Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 10/20 | 0.35 |
| ▸ | FNTB | P49356 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388271 | 1.00 | MAPT (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL332020 | 1.00 | MAPT (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Cysteine SCHEMBL20817549 | 0.90 | PTGS1 (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL11856516 | 0.85 | FNTA (0.51) | MAPTFNTAFNTBALDH1A1 | |
| SCHEMBL3863272 | 0.85 | FNTA (0.51) | MAPTFNTAFNTBALDH1A1 | |
| SCHEMBL3860439 | 0.85 | FNTA (0.51) | MAPTFNTAFNTBALDH1A1 | |
| SCHEMBL3863270 | 0.85 | FNTA (0.51) | MAPTFNTAFNTBALDH1A1 | |
| SCHEMBL20657039 | 0.84 | FNTA (0.54) | MAPTFNTAFNTBALDH1A1 | |
| SCHEMBL20535484 | 0.84 | FNTA (0.54) | MAPTFNTAFNTBALDH1A1 | |
| SCHEMBL1529433 | 0.84 | FNTA (0.54) | MAPTFNTAFNTBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765376-B1 | Topical compositions and use thereof for the treatment of epithelial-related conditions | SIGNUM BIOSCIENCES INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8338648-B2 | Topical compositions and methods for epithelial-related conditions | SIGNUM BIOSCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8334413-B2 | Topical compositions and methods for epithelial-related conditions | SIGNUM BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110117187-A1 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1765376-A4 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1899480-A4 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1899480-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1765376-A1 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006135894-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2005123103-A1 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117187-A1 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS | KRT18, CUTA, SERPINB1 | MAPT 2316/4885KDM4E 4307/4885THRB 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.